Invivyd (IVVD) Capital Expenditures (2021 - 2025)
Invivyd's (IVVD) quarterly Capital Expenditures came in at $183000.0 in Q4 2025, up 3760.0% YoY from $4740.9 in Q4 2024, and up 1930.0% on a QoQ basis from -$10000.0 in Q3 2025.
Invivyd (IVVD) Capital Expenditures (2021 - 2025) Analysis & Trends
Invivyd (IVVD) has 5 years of Capital Expenditures data on file, last reported at $183000.0 in Q4 2025.
- Quarterly Capital Expenditures rose 3760.0% year-over-year to $183000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $155000.0 (up 10.71% YoY) and the FY2025 annual result came in at $155000.0, up 10.71% from the prior year.
- Capital Expenditures climbed to $183000.0 in Q4 2025, from -$10000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $4.8 million in Q4 2022 to a low of -$3.1 million in Q1 2022.
- A 5-year average of $330062.5 and a median of -$9000.0 in 2025 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2024 — Capital Expenditures plunged 1304.81% — and 2025, when it surged 3760.0%.
- Tracing IVVD's Capital Expenditures over 5 years: stood at $3.3 million in 2021, then soared by 44.56% to $4.8 million in 2022, then sank by 100.25% to -$12000.0 in 2023, then soared by 58.33% to -$5000.0 in 2024, then surged by 3760.0% to $183000.0 in 2025.
- The last three Capital Expenditures figures came in at $183000.0 (Q4 2025), -$10000.0 (Q3 2025), and -$8000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Invivyd | 212.23 Mn | 52.15 Mn | 13.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 183,000.00 |
| Dec 31, 2025 | 183,000.00 |
| Sep 30, 2025 | -10,000.00 |
| Sep 30, 2025 | -10,000.00 |
| Jun 30, 2025 | -8,000.00 |
| Jun 30, 2025 | -8,000.00 |
| Mar 31, 2025 | -10,000.00 |
| Mar 31, 2025 | -10,000.00 |
| Dec 31, 2024 | -5,000.00 |
| Dec 31, 2024 | -5,000.00 |
| Sep 30, 2024 | -1.46 Mn |
| Sep 30, 2024 | -1.46 Mn |
| Jun 30, 2024 | -76,000.00 |
| Jun 30, 2024 | -76,000.00 |
| Mar 31, 2024 | 1.68 Mn |
| Mar 31, 2024 | 1.68 Mn |
| Dec 31, 2023 | -12,000.00 |
| Dec 31, 2023 | -12,000.00 |
| Sep 30, 2023 | -104,000.00 |
| Sep 30, 2023 | -104,000.00 |